Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells $261,266.46 in Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $28.34, for a total transaction of $261,266.46. Following the sale, the insider owned 78,731 shares of the company’s stock, valued at $2,231,236.54. This represents a 10.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Wednesday, April 1st, Campbell Rogers sold 64,533 shares of Heartflow stock. The stock was sold at an average price of $24.64, for a total transaction of $1,590,093.12.
• On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The stock was sold at an average price of $25.69, for a total transaction of $1,657,852.77.

Heartflow Stock Performance

Heartflow stock opened at $29.49 on Friday. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The firm has a 50 day moving average price of $27.73 and a 200 day moving average price of $28.52. The company has a market capitalization of $2.54 billion and a PE ratio of -9.48.

Heartflow (NASDAQ:HTFL) last posted its earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.08. The company had revenue of $52.59 million during the quarter. Heartflow’s quarterly revenue was up 41.3% on a year-over-year basis. As a group, equities research analysts forecast that Heartflow, Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of Heartflow

A number of large investors have recently modified their holdings of HTFL. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Heartflow during the third quarter worth $4,418,000. TrueMark Investments LLC purchased a new stake in shares of Heartflow during the third quarter worth $918,000. Baillie Gifford & Co. purchased a new stake in shares of Heartflow during the third quarter worth $101,182,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Heartflow during the third quarter worth $234,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Heartflow during the third quarter worth $4,015,000.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Canaccord Genuity Group dropped their target price on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a report on Friday, May 15th. William Blair assumed coverage on shares of Heartflow in a report on Monday, May 4th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. dropped their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.00.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.